Last reviewed · How we verify
XP13512
At a glance
| Generic name | XP13512 |
|---|---|
| Also known as | GSK1838262, Gabapentin Enacarbil (GEn) |
| Sponsor | XenoPort, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study (PHASE4)
- ASP8825 - Pharmacokinetics Study in Patients With Impaired Renal Function and Haemodialysis (PHASE1)
- Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients (PHASE3)
- ASP8825 - A Study to Investigate the Food Effect on the Pharmacokinetics of ASP8825 (PHASE1)
- ASP8825 - Study in Patients With Restless Legs Syndrome (PHASE2)
- Simulated Driving Study in Restless Legs Syndrome (PHASE2)
- A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment (PHASE2)
- XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XP13512 CI brief — competitive landscape report
- XP13512 updates RSS · CI watch RSS
- XenoPort, Inc. portfolio CI